Bioatla, Inc.

Biotechnology • Healthcare • San Diego, CA, United States • BCAB (NCM)

BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and squamous cell carcinoma of head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for treating melanoma, renal cell carcinoma, colorectal cancer, and NSCLC; BA3182, a bispecific candidate to treat adenocarcinomas; BA3361, a CAB-Nectin-4-ADC for treating tumors; BA3142, a dual-CAB T-cell engager targeting B7-H3, a protein expressed on various solid tumors; and preclinical candidate for CAB-Nectin 4 x CAB-CD3. The company was founded in 2007 and is headquartered in San Diego, California.

Stock Performance (90 Days)

Data through Dec 24, 2025

Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

BioAtla Stock Slips Premarket After Early Pop As Investors Weigh $40M SPV Deal For Phase 3 Cancer Trial - Stocktwits

Stocktwits • Dec 31

BioAtla announces $40 million oncology SPV investment deal - MSN

MSN • Jan 1

BioAtla Enters into Agreements for up to $22.5 Million Flexible Financing - Investing News Network

Investing News Network • Nov 20

$40M AI-driven cancer deal backs new OPSCC drug into Phase 3 test - Stock Titan

Stock Titan • Dec 31

BioAtla Secures $5 Million Initial Funding for Phase 3 Trial of Ozuriftamab Vedotin (Oz-V) in Oropharyngeal Squamous Cell Carcinoma - Quiver Quantitative

Quiver Quantitative • Dec 31

Other Biotechnology Companies

Vertex Pharmaceuticals Inc. / MA

$118.68B market cap

Regeneron Pharmaceuticals, Inc.

$82.72B market cap

Alnylam Pharmaceuticals, Inc.

Frequently Asked Questions

Has BioAtla, Inc. had layoffs?

No layoff events have been recorded for BioAtla, Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.

How many employees does BioAtla, Inc. have?

BioAtla, Inc. has approximately 61 employees.

What industry is BioAtla, Inc. in?

BioAtla, Inc. operates in the Biotechnology industry, within the Healthcare sector.

Is BioAtla, Inc. a publicly traded company?

Yes, BioAtla, Inc. is publicly traded under the ticker symbol BCAB on the NCM. The company has a market capitalization of approximately $0.04 billion.

Where is BioAtla, Inc. headquartered?

BioAtla, Inc. is headquartered in San Diego, CA, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.